Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies
X Liu, Y Lu, S Qin - Future oncology, 2021 - Taylor & Francis
Hepatocellular carcinoma (HCC) is a common cancer globally and a leading cause of
cancer-related deaths. Although early-stage disease may be curable by resection, liver …
cancer-related deaths. Although early-stage disease may be curable by resection, liver …
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies
X Liu, Y Lu, S Qin - Future Oncology, 2021 - cir.nii.ac.jp
抄録< jats: p> Hepatocellular carcinoma (HCC) is a common cancer globally and a leading
cause of cancer-related deaths. Although early-stage disease may be curable by resection …
cause of cancer-related deaths. Although early-stage disease may be curable by resection …
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.
X Liu, Y Lu, S Qin - Future Oncology (London, England), 2021 - europepmc.org
Hepatocellular carcinoma (HCC) is a common cancer globally and a leading cause of
cancer-related deaths. Although early-stage disease may be curable by resection, liver …
cancer-related deaths. Although early-stage disease may be curable by resection, liver …
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies
X Liu, Y Lu, S Qin - Future oncology (London, England), 2021 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is a common cancer globally and a leading cause of
cancer-related deaths. Although early-stage disease may be curable by resection, liver …
cancer-related deaths. Although early-stage disease may be curable by resection, liver …